Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Dimethyl Fumarate
Treatment for Multiple sclerosis
Typical Dosage: 120mg oral twice daily for 7 days, then 240mg oral twice daily
Effectiveness
82%
Safety Score
42%
Clinical Trials
103
Participants
2.6K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
42
DangerousModerateSafe
Treatment Details
Dosage Range
120mg oral twice daily for 7 days, then 240mg oral twice daily
Time to Effect
2-3 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3(Treat 3 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$85,000
Monitoring:$4,000
Side Effect Mgmt:$500
Total Annual:$89,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$110,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$114,743.59
Cost per Remission
$298,333.33
Comparison vs Interferon Beta-1a
Cost Difference
+$24,500/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Dimethyl Fumarate Outcomes
for Multiple sclerosis
Efficacy Outcomes
Overall Effectiveness
+82%
Response Rate
+78%
Remission Rate
+30%
Common Side Effects
Flushing
+40%
Abdominal pain
+18%
Diarrhea
+14%
Nausea
+12%
Lymphopenia (Grade 3/4)
+2%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
12 completed trials for Dimethyl Fumarate in Multiple sclerosis
A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
NCT05658484COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Beijing, China +14 more
Started: Jun 9, 2023
Dimethyl Fumarate (DMF) Observational Study
NCT02047097COMPLETED
5.49K participants
OBSERVATIONAL
Birmingham, United States +467 more
Started: Nov 19, 2013
Study of Utilization Patterns of Dimethyl Fumarate in Germany
NCT02969304COMPLETED
930 participants
OBSERVATIONAL
Leipzig, Germany
Started: Dec 30, 2016
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
NCT02525874COMPLETEDPHASE3
218 participants
INTERVENTIONAL
Gilbert, United States +33 more
Started: Aug 11, 2015
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
NCT01930708COMPLETEDPHASE4
1.11K participants
INTERVENTIONAL
Innsbruck, Austria +89 more
Started: Oct 31, 2013
Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis
NCT02461069COMPLETEDPHASE4
67 participants
INTERVENTIONAL
Bonn, Germany +5 more
Started: May 6, 2015
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
NCT01156311COMPLETEDPHASE2
108 participants
INTERVENTIONAL
Gilbert, United States +15 more
Started: Jun 1, 2010
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
NCT02125604COMPLETEDPHASE4
214 participants
INTERVENTIONAL
Augsburg, Germany +18 more
Started: Jun 1, 2014
Tecfidera Lymphocyte Chart Review
NCT02519413COMPLETED
483 participants
OBSERVATIONAL
Homewood, United States +9 more
Started: Jul 1, 2015
Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera
NCT04756687COMPLETED
1.51K participants
OBSERVATIONAL
Amiens, France +31 more
Started: Mar 10, 2021
Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
NCT02739542COMPLETEDPHASE4
87 participants
INTERVENTIONAL
Los Angeles, United States +10 more
Started: Mar 19, 2016
Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers
NCT04022473COMPLETEDPHASE1
210 participants
INTERVENTIONAL
Columbia, United States
Started: Jul 7, 2019
Showing 20 of 106 total trials